A Case of Delusional Parasitosis in a 58-year-old Woman
Taral R. Sharma, MD, MBA
Clinical Instructor, University of South Carolina School of Medicine, Greenville, SC; Staff Psychiatrist, South Carolina Department of Mental Health, Anderson, SC
Michal C. Cieraszynski, DO
Staff Psychiatrist, Department of Veteran’s Affairs, Salem, Va.
First published in Primary Psychiatry | October 30, 2013.
“Ms. A” is a 58 year-old white, divorced, unemployed female, with past psychiatric history of major depressive disorder and anxiety disorder NOS, who presented to emergency department (ED) with complaints of "lice and bugs" crawling from her skin and rectum for several weeks. Read >
Why Patients Choose Psychotherapy or Sertraline: From a Clinical Trial of PTSD Treatment
Stephanie Keller, MA
Doctoral Candidate; Department of Psychological Sciences, Case Western Reserve University, OH
First published in Psychiatry Weekly, October 21, 2013, 8(22).
Why do some psychiatric patients prefer a particular treatment modality—or modalities—to another? This question is particularly conspicuous in the context of treating posttraumatic stress disorder (PTSD), for which several psychotherapy protocols show robust evidence of efficacy and exactly two medications—sertraline and paroxetine—have received FDA approval. Numerous lines of research have looked at whether patient preferences for PTSD treatment are shaped by the type of trauma experienced, ethnicity, sex, psychiatric comorbidity, previous PTSD treatment, and perceptions of how or why a treatment is believed to work.
Gender Differences in Depression: Implications for Recognizing Male-Type Symptoms in the Clinic
Lisa A. Martin, PhD
Women’s & Gender Studies and Health Policy Studies, University of Michigan, Dearborn, Mich.
First published in Psychiatry Weekly, October 7, 2013, 8(21).
In most prevalence studies of major depressive disorder, roughly twice as many women than men are represented among adults with MDD. This finding is so well established as to appear nearly axiomatic, and, as a result, depression is heavily conceptualized as a female disease. Read >
Transitioning to Updated Substance Use Disorder Criteria in DSM-5
Wilson M. Compton, MD, MPE
Director, Division of Epidemiology, Services and Prevention Research; National Institute on Drug Abuse, Bethesda, Md.
First published in Psychiatry Weekly, September 2013, 8(19).
The recently published DSM-5 introduces several key changes to the section on substance use disorders (SUD). Read >
Michael Eriksen Benros, MD, PhD
National Centre for Register-based Research, Aarhus University; Mental Health Centre Copenhagen, Copenhagen University Hospital, Denmark
First published in Psychiatry Weekly, September 2013, 8(18).
The human body’s inflammatory reaction to infection has for some time been understood as a possible etiological risk factor for the development of some psychiatric disorders. It is not, however, a well-understood risk factor. Animal studies have indicated that inflammation and brain-reactive antibodies can induce neuropsychiatric symptoms. Whether this can be generalized to humans is still debatable, since similar randomized studies in humans are nearly impossible to conduct due to ethical reasons. However, using Danish national health registries, Dr. Michael Eriksen Benros and colleagues recently published the first large scale, population-based study examining the extent to which inflammation and subsequent mood disorders are related.
Nancy E. Broskie, MD
Private Practice, Salem, OR; Affiliate Assistant Professor, Oregon Health and Science University, Portland, OR
First published in Psychiatry Weekly, August 2013, 8(17).
Coenzyme Q10 (CoQ10) is an antioxidant supplement that could reduce Parkinsonism,1 aid migraine prophylaxis,2 and increase energy.3 CoQ10 is produced in the body simultaneously with cholesterol, which is inversely related to severity of both depression4 and Parkinsonism.5 Basal ganglia calcification can be caused by hypoparathyroidism with hypocalcemia.6 Two patients with low baseline parathyroid hormone (PTH) and extrapyramidal symptoms tried CoQ10 for energy and migraine prophylaxis, during which time they had transient psychosis that remitted when CoQ10 was discontinued.
Neuroscientist Robert Ferrante stands accused of poisoning his neurologist wife, Autumn Klein, both from the University of Pittsburgh. Medscape Medical News
A look at the safety, efficacy, and potential therapeutic role of the newly approved antidepressant levomilnacipran. Medscape Psychiatry
New guidelines have been developed by the Physicians Committee for Responsible Medicine. Outside experts say a healthy diet and exercise is always good advice, but evidence that this will reduce Alzheimer’s risk is lacking. Medscape Medical News
The FDA has approved a new SNRI for major depressive disorder in adults. FDA Approvals